Cardiol Therapeutics (TSE:CRDL) has released an update.
Cardiol Therapeutics has unveiled encouraging results from its Phase II MAvERIC-Pilot study of CardiolRx™ for treating recurrent pericarditis, showing significant reductions in patient-reported pain and inflammation. With 89% of participants opting to continue in the study’s extension phase, the data suggests a potential for CardiolRx™ to advance to Phase III trials as a non-immunosuppressive treatment option for pericarditis patients. The study highlights CardiolRx™’s safety and general tolerability, reinforcing the company’s commitment to addressing heart disease with novel anti-inflammatory therapies.
For further insights into TSE:CRDL stock, check out TipRanks’ Stock Analysis page.
